Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 30th Preview)
-
FDA scrutiny and revised clinical evidence for cell therapy approvals
Pierre Fabre Pharmaceuticals and Atara Biotherapeutics resubmitted Ebvallo (tabelecleucel) to the FDA after two prior rejections, seeking approval for EBV+ PTLD following transplant. The companies say the updated submission aligns with FDA expectations on the clinical path, while they characterize earlier disagreements as driven by shifting regulator positions on trial interpretability. In parallel, regulatory attention remains focused on both clinical evidence and manufacturing quality. Earlier FDA feedback included concern that the single-arm pivotal Phase 3 ALLELE study was insufficient for a BLA, even after the partners addressed GMP issues and reported no new safety concerns. Analysts cited in the reporting suggested the resubmission could land as a Class 2 BLA resubmission with a target action date into March 2027, depending on the FDA’s review scope. The resubmission keeps one of the most closely watched U.S. cell therapy pathways for a rare post-transplant indication moving forward. Separately, the same regulatory resubmission theme is echoed across other late-stage programs in this issue, highlighting that FDA decision timelines increasingly hinge on evidence-package design and regulator alignment as much as on raw endpoint magnitude.
-
Obesity pipeline escalation as Lilly’s retatrutide posts phase 3 weight-loss benchmarks
Eli Lilly’s retatrutide strengthened the next-generation obesity playbook with phase 3 data showing weight losses across doses in people with obesity and type 2 diabetes. The reports highlighted a high-dose group achieving average loss that surpassed 20% of body weight and significant metabolic improvements during an 80-week study. At a major medical meeting context, Lilly’s disclosures emphasized that a majority-level share of participants could move below obesity thresholds by study end, alongside reductions in blood sugar and cardiometabolic risk factors. Retatrutide is designed as a triple agonist targeting GLP-1, GIP, and glucagon. The data intensify competitive pressure across the obesity field, where GLP-1-centered therapies are already commercially scaled and next-generation candidates are racing to prove durability and broader metabolic benefits. Investors and clinicians are now likely to compare retatrutide’s efficacy profile against late-stage results from other triple- and multi-agonist programs. Taken together, the disclosures reinforce that obesity drug differentiation is moving from simple weight loss to integrated outcomes that include glycemic control and cardiovascular risk markers.
-
Merck’s multi-billion oncology licensing bet on KRAS G12D molecular glue from China
Merck moved to secure next-generation KRAS biology through an exclusive global licensing deal for SciBrunch Therapeutics’ preclinical oral KRAS G12D (on) molecular glue candidate SPR2015. The agreement includes $400 million upfront and milestone payments that could lift total value to $2.13 billion. The deal positions SPR2015 for development across multiple KRAS G12D-driven tumor types, including colorectal cancer, non-small cell lung cancer, and pancreatic ductal adenocarcinoma. SciBrunch presented preclinical efficacy data across CDX and PDX models at AACR, with reported objective response rates supporting differentiation for further human testing. For Merck, the transaction reflects a continued strategy shift toward precision oncology assets where specific mutation status and tumor biology are central to the development thesis. For SciBrunch, the partnership validates that the field’s appetite for KRAS-targeted modalities remains high even at preclinical stage. The licensing also adds to the growing catalog of deals linking large pharma with China-based discovery engines, with KRAS programs emerging as one of the most active target areas.
-
AstraZeneca invests $2B in Summit’s PD-1/VEGF bispecific and sets ADC combination trials
AstraZeneca finalized a $2 billion equity investment in Summit Therapeutics, taking a stake while launching clinical collaboration plans to test Summit’s ivonescimab with AstraZeneca’s antibody-drug conjugates. The investment is tied to combination trial development focused on cancer regimens that pair PD-1/VEGF signaling with ADC delivery. The agreement supports testing ivonescimab alongside AstraZeneca’s CLDN18.2-directed ADC in gastrointestinal cancers first, with broader combination exploration described across AstraZeneca’s ADC portfolio. The structure preserves separate development and commercial rights for each company’s assets. The deal follows earlier disclosed clinical signals for both ivonescimab and AstraZeneca’s ADCs, providing a rationale for pairing modalities where immunotherapy and cytotoxic payload delivery could complement each other. In market terms, AstraZeneca’s approach underscores how ADC combinations are increasingly becoming a financing and pipeline-integrating strategy rather than a purely standalone development path.
-
Novo renews obesity expansion with a weekly oral GLP-1/GIP license from Hengrui
Novo Nordisk licensed ex-China rights to Hengrui’s HRS-1596, a once-weekly oral GLP-1/GIP receptor dual agonist, in a deal valued at up to $2.6 billion including a $300 million upfront payment. Novo will pursue development and commercialization for territories outside China, Taiwan, and nearby markets. Hengrui will retain roles inside its home region while Novo expands its metabolic disease platform with a non-injectable approach that targets convenience and dosing adherence. The asset is described as Phase 1 ready, keeping it in early-stage development. The agreement arrives as Novo seeks to manage competitive pressure in obesity and extend beyond current injectable offerings. It also continues Novo’s pattern of building obesity pipelines through external in-licensing of late preclinical and early clinical assets. For the broader category, the deal adds a weekly oral candidate to the menu, potentially challenging the dominance of daily and weekly injection regimens if clinical tolerability and efficacy translate in pivotal studies.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.